ArticleAmerican journal of translational research2026
Plasma exchange-based artificial liver support system demonstrates short-term therapeutic efficacy in treating chronic severe hepatitis B.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this retrospective study, the short-term efficacy of the plasma exchange-based artificial liver support system (PE-ALSS) for chronic severe hepatitis B (CSHB) was explored.
methodsWe selected 111 CSHB patients and divided them into control (53 cases with conventional treatment) and research (58 cases with conventional treatment+PE-ALSS) groups based on the treatment they received. We then conducted inter-group comparisons regarding therapeutic effectiveness, complications, hepatic function indicators (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TBIL]), hepatic fibrosis markers (hyaluronic acid [HA], laminin [LN], type IV collagen [IV-C]), serum biochemical indices (interleukin [IL]-18, intercellular adhesion molecule-1 [ICAM-1]), coagulation function indices (prothrombin time [PT], thrombin time [TT], activated partial thromboplastin time [APTT]), and inflammatory factors (procalcitonin [PCT], IL-6). Finally, efficacy-associated determinants were identified by univariate and multivariate analysis.
resultsThe research group had a superior total effective rate (94.83% vs. 69.81%, P < 0.001) and a lower complication rate (1.72% vs. 13.21%, P < 0.001) than the control group. Post-treatment, the research group exhibited statistically lower ALT (65.59±14.21 U/L vs. 89.47±17.44 U/L), AST (78.12±19.63 U/L vs. 94.91±22.27 U/L), TBIL (24.45±5.46 μmol/L vs. 45.77±7.43 μmol/L), HA (84.83±7.00 ng/mL vs. 100.47±10.41 ng/mL), LN (69.90±8.18 ng/mL vs. 80.81±8.71 ng/mL), IV-C (76.21±5.52 ng/mL vs. 85.21±7.97 ng/mL), IL-18 (343.34±108.3 pg/mL vs. 543.92±138.18 pg/mL), ICAM-1 (282.57±128.8 μg/L vs. 406.3±158.26 μg/L), PT (13.79±4.03 s vs. 15.68±3.15 s), TT (17.97±2.91 s vs. 20.11±2.23 s), APTT (35.79±11.08 s vs. 40.06±8.09 s), PCT (2.25±0.91 μg/L vs. 3.24±1.15 μg/L), and IL-6 (46.33±10.21 pg/mL vs. 50.75±11.11 pg/mL) than controls. Moreover, treatment modality (B = -1.865, odds ratio = 0.155, 95% confidence interval: 0.038-0.628) was an independent determinant of efficacy (P=0.009).
conclusionPE-ALSS has significant short-term efficacy for CSHB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.